BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25444748)

  • 1. Biomarkers for neuromyelitis optica.
    Chang KH; Ro LS; Lyu RK; Chen CM
    Clin Chim Acta; 2015 Feb; 440():64-71. PubMed ID: 25444748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of neuromyelitis optica].
    Fujihara K
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):129-35. PubMed ID: 22576570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathogenesis of neuromyelitis optica].
    Misu T; Fujihara K
    Nihon Rinsho; 2013 May; 71(5):823-8. PubMed ID: 23777089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link.
    Jarius S; Wildemann B
    Med Hypotheses; 2013 Dec; 81(6):1090-5. PubMed ID: 24182872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
    Misu T; Fujihara K; Itoyama Y
    Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [NMO spectrum disorders and anti AQP4 antibody].
    Takai Y; Misu T; Takahashi T; Nakashima I; Fujihara K
    Brain Nerve; 2013 Apr; 65(4):333-43. PubMed ID: 23568981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica and astrocytic damage in its pathogenesis.
    Fujihara K
    J Neurol Sci; 2011 Jul; 306(1-2):183-7. PubMed ID: 21396661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.
    Lucchinetti CF; Guo Y; Popescu BF; Fujihara K; Itoyama Y; Misu T
    Brain Pathol; 2014 Jan; 24(1):83-97. PubMed ID: 24345222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica.
    Takano R; Misu T; Takahashi T; Izumiyama M; Fujihara K; Itoyama Y
    Tohoku J Exp Med; 2008 May; 215(1):55-9. PubMed ID: 18509235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.
    Kurosawa K; Misu T; Takai Y; Sato DK; Takahashi T; Abe Y; Iwanari H; Ogawa R; Nakashima I; Fujihara K; Hamakubo T; Yasui M; Aoki M
    Acta Neuropathol Commun; 2015 Dec; 3():82. PubMed ID: 26637322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
    Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications.
    Uzawa A; Mori M; Kuwabara S
    Brain Pathol; 2014 Jan; 24(1):67-73. PubMed ID: 24345220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders.
    Kira J
    J Neurol Sci; 2011 Dec; 311(1-2):69-77. PubMed ID: 21962794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis].
    Misu T; Takahashi T; Nakashima I; Fujihara K; Itoyama Y
    Rinsho Byori; 2009 Mar; 57(3):262-70. PubMed ID: 19363997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report.
    Misu T; Fujihara K; Nakamura M; Murakami K; Endo M; Konno H; Itoyama Y
    Tohoku J Exp Med; 2006 Jul; 209(3):269-75. PubMed ID: 16778375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biomarkers in neuromyelitis optica].
    Misu T; Takahashi T; Nakashima I; Fujihara K
    Brain Nerve; 2012 May; 64(5):525-35. PubMed ID: 22570066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New insights into the pathogenesis of neuromyelitis optica].
    Misu T; Takahashi T; Nishiyama S; Takano R; Nakashima I; Fujihara K; Itoyama Y
    Brain Nerve; 2010 Sep; 62(9):921-31. PubMed ID: 20844303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.